Deals Of The Week Examines How Amarin Reeled In A Partner For Vascepa
Amarin signed Kowa Pharmaceuticals America as a commercial partner for its fish oil pill, more than doubling the number of sales reps detailing the medicine. Forma signed a second drug discovery pact with Celgene, while Baxter bolstered its hemophilia franchise by buying out partner Chatham Therapeutics.
You may also be interested in...
The biotech has been making lemonade of its fight with FDA for expanded use of its fish-oil drug Vascepa by upping its promotion of the current indication, but executives continue to sound pessimistic about winning over the agency.
Fish oil treatment is the first to offer a dosing regimen of as few as two capsules, once a day, with our without food, AstraZeneca said.
While planning to split into two companies, one focused on its successful hemophilia franchise, Baxter fully acquires Phase I/II gene therapy program for hemophilia B. Baxter has been seeking ways to bolster its hemophilia business in the face of coming competition from the likes of Biogen Idec.